NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE
Post# of 341
(Total Views: 232)
Posted On: 08/30/2022 5:07:06 PM
NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Dosing Participants in CYB003 Trial for Treatment of MDD
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced a clinical milestone: the first two participants in its phase 1/2a trial evaluating CYB003 for the treatment of major depressive disorder (“MDD”) have been dosed. According to the announcement, CYB003 is the first-ever novel psilocybin analog to enter clinical development. The company is conducting a randomized, double-blind, placebo-controlled study evaluating people with moderate to severe MDD in which participants will receive two administrations (placebo/active and active/active) with a response assessed at week 3 after first dose and at week 6 after second dose. “To commence dosing in our first-in-human phase 1/2a trial is a tremendous milestone for Cybin, especially having reached the clinic within just 18 months,” said Cybin CEO Doug Drysdale in the press release. “Our goal continues to focus on becoming a leader in creating the best psychedelic therapies for patients and today we have moved one step closer. Through our rigorous preclinical work and ongoing clinical development of CYB003, we believe we have the potential to unlock the powerful benefits of psilocybin for the treatment of MDD without its well-known limitations. . . . The high level of participant interest in our study serves to validate the significant unmet need for alternative and better treatment options to improve mental health conditions. We expect that this phase 1/2a trial will provide valuable insights and data. These findings will be critical in establishing a safe and efficacious treatment profile for CYB003 so we can continue to progress our mission to help revolutionize the treatment landscape for people suffering from depression.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced a clinical milestone: the first two participants in its phase 1/2a trial evaluating CYB003 for the treatment of major depressive disorder (“MDD”) have been dosed. According to the announcement, CYB003 is the first-ever novel psilocybin analog to enter clinical development. The company is conducting a randomized, double-blind, placebo-controlled study evaluating people with moderate to severe MDD in which participants will receive two administrations (placebo/active and active/active) with a response assessed at week 3 after first dose and at week 6 after second dose. “To commence dosing in our first-in-human phase 1/2a trial is a tremendous milestone for Cybin, especially having reached the clinic within just 18 months,” said Cybin CEO Doug Drysdale in the press release. “Our goal continues to focus on becoming a leader in creating the best psychedelic therapies for patients and today we have moved one step closer. Through our rigorous preclinical work and ongoing clinical development of CYB003, we believe we have the potential to unlock the powerful benefits of psilocybin for the treatment of MDD without its well-known limitations. . . . The high level of participant interest in our study serves to validate the significant unmet need for alternative and better treatment options to improve mental health conditions. We expect that this phase 1/2a trial will provide valuable insights and data. These findings will be critical in establishing a safe and efficacious treatment profile for CYB003 so we can continue to progress our mission to help revolutionize the treatment landscape for people suffering from depression.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)